PURE Bioscience, Inc.
PURE · OTC
7/31/2025 | 7/31/2024 | 7/31/2023 | 7/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $5 | $0 | $0 | $0 |
| Enterprise Value | $5 | $0 | $0 | $0 |
| Revenue | $2 | $0 | $0 | $0 |
| % Growth | 112,075.2% | 4.6% | 1.3% | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 59.2% | 58.7% | 51.7% | 54% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -0.1% | -155.2% | -204% | -176.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -0.1% | -170.7% | -211% | -188.7% |
| EPS Diluted | -0.021 | -0.03 | -0.036 | -0.039 |
| % Growth | 28.4% | 16% | 9.6% | – |
| Operating Cash Flow | -$2 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$2 | -$0 | -$0 | -$0 |